Results 31 to 40 of about 81,297 (236)
Iron Catalyzed Aryl–Aryl Kumada Cross‐Coupling: A Mechanistic and Computational Investigation
Angewandte Chemie, EarlyView.Despite intense interest, the mechanism of iron‐catalyzed aryl–aryl cross‐coupling remains poorly understood. Combining Mössbauer spectroscopy, kinetics analysis, and DFT computations these studies reveal a novel Fe(I)/Fe(II)/Fe(III) catalytic for aryl–aryl cross‐coupling mediated by an Fe(II) PCNHCP Pincer complex. These findings close a key knowledge
Jatin Panda +11 more
wiley +2 more sources
Frontiers in Pharmacology, 2023 Dyslipidemia due to renal insufficiency is a common complication in patients with chronic kidney diseases (CKD), and a major risk factor for the development of cardiovascular events.
Zebin Jiang +13 more
doaj +1 more source
Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus [PDF]
, 2013 Purpose: This paper reports the results of an audit that assessed the prevalence of residual hypertriglyceridemia and the potential need for intensified management among patients with statin-treated type 2 diabetes mellitus (T2DM) in primary care in the ...
Feher, Michael D. +2 more
core +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2019 The drug–drug interaction profile of atorvastatin confirms that disposition is determined by cytochrome P450 (CYP) 3A4 and organic anion transporting polypeptides (OATPs).
Bridget L. Morse +9 more
doaj +1 more source
Frontiers in Pharmacology, 2015 Several clinical trials have substantiated the efficacy of the co-administration of statins like atorvastatin and fibrates. Without information currently available about the interaction between the two drugs, a pharmacokinetic study was conducted to ...
Omar ePatiño-Rodríguez +9 more
doaj +1 more source
Physicians' Experiences as Patients with Statin Side Effects: A Case Series. [PDF]
, 2017 Physicians are among those prescribed statins and therefore, subject to potential statin adverse effects (AEs). There is little information on the impact of statin AEs on physicians affected by them. We sought to assess the character and impact of statin
Golomb, Beatrice Alexandra +2 more
core +2 more sources
Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
Pharmaceuticals, 2022 The interaction between statins and omega-3 fatty acids remains controversial. The aim of this phase 1 trial was to evaluate the pharmacokinetics of drug-drug interaction between atorvastatin and omega-3 fatty acids.
Jae Hoon Kim +10 more
doaj +1 more source
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. [PDF]
, 2017 Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma.
Alderete, Benjamin +7 more
core +1 more source
Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers
Advanced Functional Materials, EarlyView.A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley +1 more source